Condition: Neoplasms · Bone Marrow Transplantation · Sponsor: Murdoch Childrens Research Institute
A prospective, open, randomised implementation study in paediatric cancer patients. The study aims to determine whether a personalised approach will result in an overall reduction in clinically relevant adverse drug reactions (ADRs) and to evaluate the economic and quality of life impacts. Participants will be randomised to receive personalised guided prescribing of supportive care therapy (study arm) or standard of care (control arm) for a period of 12 weeks. The follow up period includes prospective patient reporting of symptoms and quality of life through electronically delivered surveys, for a maximum of 12 months.
This description comes directly from the study's public registry record.
Tayla Stenta · 03 9345 5533 · pharmaco.genomics@mcri.edu.au
Claire Moore · 03 9345 5533 · pharmaco.genomics@mcri.edu.au
Always discuss trial participation with your own doctor first.
| Sydney Children's Hospital | Randwick, New South Wales, Australia | Recruiting |
| Women's and Children's Hospital | North Adelaide, South Australia, Australia | Recruiting |
| The Royal Children's Hospital | Parkville, Victoria, Australia | Recruiting |
| Perth Children's Hospital | Nedlands, Washington, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05667766